Entinostat - Syndax Pharmaceuticals

Drug Profile

Entinostat - Syndax Pharmaceuticals

Alternative Names: EDP-103; Entinostat; KHK-2375; MS-27-275; MS-275; SNDX-275

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nihon Schering; Pfizer; University of Tokyo
  • Developer Columbia University; Eddingpharm; Genentech; Indiana University; Kyowa Hakko Kirin; Memorial Sloan-Kettering Cancer Center; Merck & Co; National Cancer Institute (USA); Pfizer; Roswell Park Cancer Institute; Syndax Pharmaceuticals
  • Class Antineoplastics; Benzamides; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Breast cancer
  • Phase II Cholangiocarcinoma; Colorectal cancer; Endometrial cancer; Follicular lymphoma; Hodgkin's disease; Leukaemia; Malignant melanoma; Neuroendocrine tumours; Non-small cell lung cancer; Pancreatic cancer; Uveal melanoma
  • Phase I/II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Renal cell carcinoma

Most Recent Events

  • 17 Apr 2018 Prometheus Laboratories in collaboration with Syndax Pharmaceuticals plans a phase II trial for Renal Cell Carcinoma (Late-stage disease) in USA (NCT03501381)
  • 22 Mar 2018 Syndax Pharmaceuticals plans the Breast 49 phase I study for Breast Cancer (Metastatic disease, Late-stage disease) in August 2018 (NCT03473639)
  • 10 Jan 2018 Syndax Pharmaceuticals and Genentech collaborated to conduct a phase Ib/II trial for Breast cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top